A detailed history of Innovis Asset Management LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Innovis Asset Management LLC holds 63,179 shares of AUTL stock, worth $212,913. This represents 0.06% of its overall portfolio holdings.

Number of Shares
63,179
Previous 63,179 -0.0%
Holding current value
$212,913
Previous $150 Million 2.1%
% of portfolio
0.06%
Previous 0.06%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 03, 2023

SELL
$1.64 - $3.21 $103,200 - $201,995
-62,927 Reduced 49.9%
63,179 $150 Million
Q1 2023

May 10, 2023

BUY
$1.75 - $2.25 $220,685 - $283,738
126,106 New
126,106 $232 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $306M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Innovis Asset Management LLC Portfolio

Follow Innovis Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Innovis Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Innovis Asset Management LLC with notifications on news.